WALTHAM, MA, December 17, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive topline data on November 22, 2019 for its pivotal corneal wound repair study. The Company is currently evaluating several…
WALTHAM, MA, January 6, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed enrollment in its follow-on pilot study for punctate epitheliopathies (“PE”) with a focus on patients with dry eye. The study…
WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The study enrolled a…
Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers -Trial remains on track with topline data expected in Q4 2021- WALTHAM, MA, September 8, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating…
WALTHAM, MA, April 01, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have…
WALTHAM, MA, December 21, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes Pharma (“Panoptes”), a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment…
Patent Further Strengthens EyeGate’s Global IP Protection for Lead Product Candidate, EGP-437 WALTHAM, Mass., January 23, 2017 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has been granted…
WALTHAM, Mass., July 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 25% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…
WALTHAM, MA, August 29, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019,…
WALTHAM, Mass., April 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering the utility of its iontophoretic…